Inspirion Delivery Sciences Receives FDA Approval for RoxyBond tablets CII

May 1, 2017

The FDA has approved Inspirion Delivery Science’s RoxyBond (oxycodone hydrochloride) tablets for management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

The drug is an abuse-deterrent formulation of oxycodone that uses physical and chemical barriers to deter abuse.

RoxyBond forms a viscous material that resists passage through a needle; it was also more difficult to prepare solutions suitable for intravenous injection.

View today's stories